{"pageContent": "Background: Patients with advanced prostate cancer eventually cease to respond to hormonal therapy and thus progress to hormone refractory prostate cancer (HRPC). Prednisone has been used in this setting; however, limited data is available for this monotherapy in the asymptomatic HRPC population.", "metaData": {"source": "Couples surviving prostate cancer: challenges in their lives and relationships\nhttps://pubmed.ncbi.nlm.nih.gov/22018409/"}}